Dr. McGregor on Immunotherapy Combinations in Kidney Cancer

Bradley McGregor, MD
Published: Friday, Apr 06, 2018



Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Two phase III trials that are investigating immunotherapy combinations are CheckMate-214 and IMmotion151. CheckMate-214 investigated nivolumab (Opdivo) and ipilimumab (Yervoy), whereas IMmotion151 investigated atezolizumab (Tecentriq) and bevacizumab (Avastin). The CheckMate-214 study saw impressive complete response (CR) rates of 16% for patients with PD-L1 expression.

IMmotion151 also had a CR rate of 9%. The most appealing aspect of that trial was the low toxicity profile. In CheckMate-214, it seemed to only work best for intermediate- and poor-risk patients, says McGregor. But, in the IMmotion151 study, there was a benefit across all subgroups, independent of risk status.

There are multiple ongoing phase III trials inspired by phase I data that showed impressive response rates. The hope is that those response rates translate into the phase III trials and improve CR rates.
 
SELECTED
LANGUAGE


Bradley McGregor, MD, physician, Genitourinary Oncology program, Dana-Farber Cancer Institute, instructor of medicine, Harvard Medical School, discusses combinations of immunotherapy for patients with kidney cancer.

Two phase III trials that are investigating immunotherapy combinations are CheckMate-214 and IMmotion151. CheckMate-214 investigated nivolumab (Opdivo) and ipilimumab (Yervoy), whereas IMmotion151 investigated atezolizumab (Tecentriq) and bevacizumab (Avastin). The CheckMate-214 study saw impressive complete response (CR) rates of 16% for patients with PD-L1 expression.

IMmotion151 also had a CR rate of 9%. The most appealing aspect of that trial was the low toxicity profile. In CheckMate-214, it seemed to only work best for intermediate- and poor-risk patients, says McGregor. But, in the IMmotion151 study, there was a benefit across all subgroups, independent of risk status.

There are multiple ongoing phase III trials inspired by phase I data that showed impressive response rates. The hope is that those response rates translate into the phase III trials and improve CR rates.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x